ReviewCells2026
Nasal Cytology as a Cellular Window into Epithelial Dysfunction and Type 2 Inflammation: From Mechanisms to Translational Implications.
Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nasal Cytology as a Complementary Cellular Window in Severe Asthma Phenotyping: Comments on the BRISA Study [Letter].Journal of asthma and allergy · 2026Article
- The airway epithelial-immune axis: mechanisms and therapeutic implications.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial barrier dysfunction is increasingly recognized as a central pathogenic mechanism in chronic inflammatory airway diseases characterized by type 2 immune responses. Chronic rhinosinusitis with nasal polyps (CRSwNP) represents a paradigmatic condition in which structural epithelial alterations, impaired barrier integrity, and sustained release of epithelial-derived alarmins interact with innate and adaptive immune pathways to drive persistent inflammation and tissue remodeling. In this context, understanding disease heterogeneity requires tools capable of capturing cellular and immunological complexity beyond purely molecular or symptom-based classifications. Nasal cytology is a standardized, minimally invasive, and repeatable technique that provides direct in vivo assessment of epithelial morphology and inflammatory cell infiltrates at the mucosal surface. By identifying distinct cytological patterns, including eosinophil-dominant, mast cell-rich, and mixed inflammatory signatures, nasal cytology reflects the underlying immunopathological mechanisms of CRSwNP and correlates with disease severity, clinical control, and therapeutic responsiveness. Its dynamic nature allows longitudinal monitoring of inflammatory changes over time, offering insights that complement clinical evaluation and endoscopic assessment. This review integrates current knowledge on epithelial barrier dysfunction and type 2 inflammation with the translational relevance of nasal cytology in CRSwNP. Particular attention is given to its role in disease phenotyping, prognostic stratification, and monitoring of biologic therapies. Within precision medicine frameworks, nasal cytology emerges as a robust cellular biomarker bridging epithelial biology, immune profiling, and personalized clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.